, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics
was founded in 2004 and is headquartered in Ramsey, New Jersey.
BREAKING NEWS TODAY - 07/30/2020
shares are trading higher following a report suggesting the company is near receiving emergency use authorization of Convalescent Plasma in COVID-19 patients.
On July 6, 20, ADMA
opened a new plasma facility and is awaiting emergency authorization for a second location.
With the FDA asking for everyone to donate plasma, this stock could rip!
Plasma stocks ripped today and continue to rip.
This company already is up and running one plasma facility.
The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.